AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment o

William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radio

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

AZN's pipeline setbacks weigh on its stock, but a deep late-stage pipeline and 20+ expected readouts

Prefer to listen? Hear this as a ~5-minute audio briefing on The GuruFocus Brief.Stock NewsFed raise

AstraZeneca and Daiichi Sankyo said on Thursday their breast cancer treatment Enhertu has been appro

On Monday, AstraZeneca (NASDAQ:AZN) discussed second-quarter financial results during its earnings c

AstraZeneca plc (AZN) rose 2.16% intraday after J.P. Morgan reiterated an Overweight rating, pointin

William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead

The recommendations of Wall Street analysts are often relied on by investors when deciding whether t

Prefer to listen? Hear this as a ~5-minute audio briefing on The GuruFocus Brief.Stock NewsFed poise

AstraZeneca PLC (LON: AZN - Get Free Report) insider Michel Demare bought 2,500 shares of AstraZenec

Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Ceri

CNBC traders picked AstraZeneca, Leidos, 10-year Treasuries and Expeditors; strong earnings lifted L

APTV, AZN and OZK have been added to the Zacks Rank #5 (Strong Sell) List on September 15th, 2026.

In the latest trading session, Astrazeneca (AZN) closed at $163.78, marking a +2.25% move from the p

AstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer stu

Cellectis (NASDAQ: CLLS) pivots to in vivo gene editing, extending cash runway to H2 2028. Read pipe

DALLAS--(BUSINESS WIRE)--Susan G. Komen®, the world's leading breast cancer organization, has announ

AstraZeneca announced long-term survival data for Tagrisso and Enhertu in lung cancer, alongside bre

The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast can

Longest survival data ever reported in a global Phase III trial in this settingNew data reinforce TA

6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapyAstraZene

Astrazeneca NYSE: AZN presented Phase III data for tozorakimab in chronic obstructive pulmonary dise

Wainua's July failure erased more than $30 billion of AstraZeneca's market value and raised question

AstraZeneca stock toppled in late trades Friday after the company's experimental breast cancer treat

AstraZeneca ​said on ‌Friday ​its ​breast cancer ⁠drug ​failed to ​meet the ​main ​goal of improving

Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, poten

Cramer avoids AstraZeneca, Joby and Grab; favors Trinity, Nucor over Reliance, and praises Simon Pro

AstraZeneca secured FDA approval for its breast cancer drug Etcamah and reported positive Phase 3 tr

https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-demonstrated-statistically-

AstraZeneca announced positive Phase 3 lung cancer trial results and earned EU approval for its Enhe

AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophil

Statistically significant and clinically meaningful disease and symptom improvements compared to pla

Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Pla

The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (dat

BioMarin Pharmaceutical agrees to acquire Alesta Therapeutics for $275 million upfront, securing ALE

AstraZeneca reports mixed lung cancer trial data, highlighting successes for Tagrisso and Enhertu wh

AstraZeneca and Daiichi Sankyo’s ENHERTU is the first and only HER2-directed medicine to improve pro

First global Phase III trial to show significant progression-free and overall survival benefits in t

Daiichi Sankyo and AstraZeneca’s Enhertu is the first and only HER2 directed medicine to improve pro

Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA

Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating a

https://youtu.be/H_RititNE8U

SOPHiA GENETICS (NASDAQ:SOPH) today announced a new global collaboration to develop, validate, and d

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation

Falling Oil Please click here for an enlarged chart of United States Oil ETF (NYSE:USO). N

Bristol Myers Squibb and AstraZeneca in talks for a $400B mega-merger, potentially creating the worl

Jim Cramer senses a 'fake out' in the rumored $400B AstraZeneca and Bristol Myers Squibb meg